Assenagon Asset Management S.A. Decreases Stock Holdings in Accuray Incorporated (NASDAQ:ARAY)

Assenagon Asset Management S.A. lessened its position in shares of Accuray Incorporated (NASDAQ:ARAY) by 22.3% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 164,999 shares of the medical equipment provider’s stock after selling 47,331 shares during the quarter. Assenagon Asset Management S.A. owned about 0.16% of Accuray worth $295,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in ARAY. Ameriprise Financial Inc. purchased a new stake in shares of Accuray during the 4th quarter valued at approximately $35,000. Prudential Financial Inc. purchased a new stake in shares of Accuray during the 4th quarter valued at approximately $43,000. ProShare Advisors LLC raised its position in shares of Accuray by 50.7% during the 4th quarter. ProShare Advisors LLC now owns 27,308 shares of the medical equipment provider’s stock valued at $54,000 after buying an additional 9,187 shares during the period. Susquehanna Fundamental Investments LLC purchased a new stake in shares of Accuray during the 4th quarter valued at approximately $66,000. Finally, Gabelli Funds LLC raised its position in shares of Accuray by 12.5% during the 4th quarter. Gabelli Funds LLC now owns 45,000 shares of the medical equipment provider’s stock valued at $89,000 after buying an additional 5,000 shares during the period. Hedge funds and other institutional investors own 64.08% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Wall Street Zen raised shares of Accuray from a “hold” rating to a “buy” rating in a research report on Friday, May 30th.

Accuray Price Performance

Shares of NASDAQ ARAY opened at $1.23 on Friday. The firm has a market cap of $126.70 million, a price-to-earnings ratio of -24.60 and a beta of 1.30. The company has a quick ratio of 0.92, a current ratio of 1.64 and a debt-to-equity ratio of 3.35. Accuray Incorporated has a 52-week low of $1.14 and a 52-week high of $2.95. The business’s 50 day moving average is $1.48 and its two-hundred day moving average is $1.83.

Accuray (NASDAQ:ARAY) last announced its earnings results on Wednesday, April 30th. The medical equipment provider reported ($0.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.04. The company had revenue of $113.24 million for the quarter, compared to analyst estimates of $101.53 million. Accuray had a return on equity of 1.43% and a net margin of 0.14%. Research analysts predict that Accuray Incorporated will post 0.01 EPS for the current year.

Accuray Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.